Comparison
Maridebart Cafraglutide vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
910463-68-2
Molecular weight
no data
4113.6 g/mol
Half-life
no data
165 h
Sequence
no data
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
3
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
5
Legal status
Full entries
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Semaglutid?
- Maridebart Cafraglutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Semaglutid?
- The highest available evidence level is "Human RCT" for Maridebart Cafraglutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Semaglutid in Germany and the United States?
- Germany: Maridebart Cafraglutide — Unapproved, Semaglutid — Prescription. United States: Maridebart Cafraglutide — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.